<p>Zevin Asset Management LLC 在最近向证券交易委员会提交的 13F 表格中披露，其在诺华制药 (NYSE:NVS - 免费报告) 的持股在第二季度减少了 2.1%。该公司在此期间出售了 2,173 股后，持有 99,336 股诺华的股票。诺华占 Zevin Asset Management LLC 投资组合的 1.7%，是其第 24 大持股。根据其最近向证券交易委员会的申报，Zevin Asset Management LLC 在诺华的持股价值为 12,021,000 美元。</p>
<ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
<p>其他一些对冲基金和机构投资者也增加或减少了在 NVS 的持股。Brighton Jones LLC 在第四季度将其在诺华的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股诺华的股票，价值 599,000 美元，此前在此期间又购买了 2,666 股。Concurrent Investment Advisors LLC 在第一季度将其在诺华的持股增加了 39.9%。Concurrent Investment Advisors LLC 目前持有 5,795 股诺华的股票，价值 646,000 美元，此前在上一季度又购买了 1,652 股。Valeo Financial Advisors LLC 在第一季度将其在诺华的持股增加了 25.9%。Valeo Financial Advisors LLC 目前持有 8,520 股诺华的股票，价值 950,000 美元，此前在上一季度又收购了 1,755 股。Nisa Investment Advisors LLC 在第一季度将其在诺华的持股增加了 19.6%。Nisa Investment Advisors LLC 目前持有 1,222 股诺华的股票，价值 136,000 美元，此前在上一季度又收购了 200 股。最后，POM Investment Strategies LLC 在第一季度将其在诺华的持股增加了 1,275.0%。POM Investment Strategies LLC 目前持有 495 股诺华的股票，价值 55,000 美元，此前在上一季度又收购了 459 股。13.12% 的股票由机构投资者持有。</p>
<h2>分析师设定新目标价</h2>
<p>NVS 已成为多份分析师报告的主题。Weiss Ratings 在 10 月 31 日的研究报告中重申了对诺华股票的 &#34;买入 (b-)&#34; 评级。Jefferies Financial Group 在 10 月 27 日的研究报告中重申了对诺华股票的 &#34;持有&#34; 评级。HC Wainwright 在 10 月 27 日的研究报告中将诺华的评级下调至 &#34;中性&#34;。Cfra Research 在 10 月 29 日的研究报告中将诺华的评级上调至 &#34;持有&#34;。最后，摩根士丹利在 9 月 12 日的研究报告中重申了对诺华的 &#34;卖出&#34; 评级，并给出了 118.00 美元的目标价（之前为 119.00 美元）。一位股票研究分析师给予该股票 &#34;强烈买入&#34; 评级，三位给予 &#34;买入&#34; 评级，六位给予 &#34;持有&#34; 评级，三位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，诺华目前的共识评级为 &#34;持有&#34;，共识目标价为 122.33 美元。</p>
<ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
<p><strong>查看我们最新的诺华股票报告</strong></p>
<h2>诺华的价格表现</h2>
<p>诺华股票在周五开盘价为 126.49 美元。该公司的流动比率为 0.88，速动比率为 0.62，债务与股本比率为 0.50。该公司的市值为 2672 亿美元，市盈率为 17.25，PEG 比率为 1.93，贝塔值为 0.60。诺华 AG 的 12 个月低点为 96.06 美元，12 个月高点为 133.55 美元。该公司的 50 日简单移动平均线为 127.30 美元，200 日简单移动平均线为 120.55 美元。</p>
<ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
<p>诺华 (NYSE:NVS - 获取免费报告) 最近在 10 月 28 日宣布了其季度财报。该公司报告本季度每股收益 (EPS) 为 2.25 美元，低于分析师的共识预期 2.26 美元，差额为 0.01 美元。该公司本季度的收入为 139.1 亿美元，而共识预期为 137 亿美元。诺华的净利润率为 26.49%，股本回报率为 41.21%。该公司的收入同比增长 8.5%。在去年同期，该公司每股收益为 2.06 美元。卖方分析师预测诺华 AG 本年度将发布 8.45 美元的每股收益。</p>
<h2>关于诺华</h2>
<p>(免费报告)</p>
<p>诺华 AG 从事医疗产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>投资汽车股票</li>
<li>防御性投资：三只报告强劲第三季度收益的分红股票</li>
<li>如何投资 FAANG 股票</li>
<li>为什么投资者不应害怕微软股票的下跌</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>DigitalOcean 的潮流已转变：准备迎接浪潮</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在诺华吗？</h2>
<p>在考虑诺华之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而诺华并不在名单上。</p>
<p>虽然诺华制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

诺华制药

<p>Zevin Asset Management LLC 已将其在诺华制药的持股比例减少了 2.1%，在第二季度出售了 2,173 股，剩余持股为 99,336 股，价值约为 1200 万美元。该公司将诺华列为其第 24 大持股。其他机构投资者也对诺华的持仓进行了调整。分析师对该股票的评级意见不一，普遍评级为 “持有”，目标价格为 122.33 美元。诺华最近报告每股收益为 2.25 美元，略低于预期，营收为 139.1 亿美元，同比增长 8.5%</p>

<p>Zevin Asset Management LLC lowered its stake in shares of Novartis AG (NYSE:NVS - Free Report) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 99,336 shares of the company's stock after selling 2,173 shares during the period. Novartis makes up 1.7% of Zevin Asset Management LLC's investment portfolio, making the stock its 24th biggest holding. Zevin Asset Management LLC's holdings in Novartis were worth $12,021,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>Zevin Asset Management LLC 在最近向证券交易委员会提交的 13F 表格中披露，其在诺华制药 (NYSE:NVS - 免费报告) 的持股在第二季度减少了 2.1%。该公司在此期间出售了 2,173 股后，持有 99,336 股诺华的股票。诺华占 Zevin Asset Management LLC 投资组合的 1.7%，是其第 24 大持股。根据其最近向证券交易委员会的申报，Zevin Asset Management LLC 在诺华的持股价值为 12,021,000 美元。</p>
</div><ul>
<li>Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver</li>
</ul>
<div class="lb-trans"><ul>
<li>诺华的月球计划癌症疗法可能成为未来的增长驱动力</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also added to or reduced their stakes in NVS. Brighton Jones LLC raised its position in shares of Novartis by 76.5% during the fourth quarter. Brighton Jones LLC now owns 6,153 shares of the company's stock worth $599,000 after purchasing an additional 2,666 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Novartis by 39.9% during the first quarter. Concurrent Investment Advisors LLC now owns 5,795 shares of the company's stock valued at $646,000 after buying an additional 1,652 shares during the last quarter. Valeo Financial Advisors LLC increased its position in shares of Novartis by 25.9% during the first quarter. Valeo Financial Advisors LLC now owns 8,520 shares of the company's stock worth $950,000 after acquiring an additional 1,755 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Novartis by 19.6% during the first quarter. Nisa Investment Advisors LLC now owns 1,222 shares of the company's stock worth $136,000 after acquiring an additional 200 shares in the last quarter. Finally, POM Investment Strategies LLC raised its holdings in shares of Novartis by 1,275.0% in the 1st quarter. POM Investment Strategies LLC now owns 495 shares of the company's stock worth $55,000 after acquiring an additional 459 shares during the last quarter. 13.12% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也增加或减少了在 NVS 的持股。Brighton Jones LLC 在第四季度将其在诺华的持股增加了 76.5%。Brighton Jones LLC 目前持有 6,153 股诺华的股票，价值 599,000 美元，此前在此期间又购买了 2,666 股。Concurrent Investment Advisors LLC 在第一季度将其在诺华的持股增加了 39.9%。Concurrent Investment Advisors LLC 目前持有 5,795 股诺华的股票，价值 646,000 美元，此前在上一季度又购买了 1,652 股。Valeo Financial Advisors LLC 在第一季度将其在诺华的持股增加了 25.9%。Valeo Financial Advisors LLC 目前持有 8,520 股诺华的股票，价值 950,000 美元，此前在上一季度又收购了 1,755 股。Nisa Investment Advisors LLC 在第一季度将其在诺华的持股增加了 19.6%。Nisa Investment Advisors LLC 目前持有 1,222 股诺华的股票，价值 136,000 美元，此前在上一季度又收购了 200 股。最后，POM Investment Strategies LLC 在第一季度将其在诺华的持股增加了 1,275.0%。POM Investment Strategies LLC 目前持有 495 股诺华的股票，价值 55,000 美元，此前在上一季度又收购了 459 股。13.12% 的股票由机构投资者持有。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>NVS has been the subject of a number of analyst reports. Weiss Ratings reiterated a &#34;buy (b-)&#34; rating on shares of Novartis in a research note on Friday, October 31st. Jefferies Financial Group reaffirmed a &#34;hold&#34; rating on shares of Novartis in a research report on Monday, October 27th. HC Wainwright lowered Novartis to a &#34;neutral&#34; rating in a research report on Monday, October 27th. Cfra Research upgraded Novartis to a &#34;hold&#34; rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group reiterated a &#34;sell&#34; rating and issued a $118.00 target price (down previously from $119.00) on shares of Novartis in a research note on Friday, September 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, six have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Novartis presently has a consensus rating of &#34;Hold&#34; and a consensus price target of $122.33.</p>
<div class="lb-trans"><p>NVS 已成为多份分析师报告的主题。Weiss Ratings 在 10 月 31 日的研究报告中重申了对诺华股票的 &#34;买入 (b-)&#34; 评级。Jefferies Financial Group 在 10 月 27 日的研究报告中重申了对诺华股票的 &#34;持有&#34; 评级。HC Wainwright 在 10 月 27 日的研究报告中将诺华的评级下调至 &#34;中性&#34;。Cfra Research 在 10 月 29 日的研究报告中将诺华的评级上调至 &#34;持有&#34;。最后，摩根士丹利在 9 月 12 日的研究报告中重申了对诺华的 &#34;卖出&#34; 评级，并给出了 118.00 美元的目标价（之前为 119.00 美元）。一位股票研究分析师给予该股票 &#34;强烈买入&#34; 评级，三位给予 &#34;买入&#34; 评级，六位给予 &#34;持有&#34; 评级，三位给予 &#34;卖出&#34; 评级。根据 MarketBeat.com 的数据，诺华目前的共识评级为 &#34;持有&#34;，共识目标价为 122.33 美元。</p>
</div><ul>
<li>3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.</li>
</ul>
<div class="lb-trans"><ul>
<li>三只大型制药股在美国投资超过 1000 亿美元。</li>
</ul>
</div><p><strong>Check Out Our Latest Stock Report on Novartis</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的诺华股票报告</strong></p>
</div><h2>Novartis Price Performance</h2>
<div class="lb-trans"><h2>诺华的价格表现</h2>
</div><p>Novartis stock opened at $126.49 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.50. The company has a market cap of $267.20 billion, a price-to-earnings ratio of 17.25, a PEG ratio of 1.93 and a beta of 0.60. Novartis AG has a 12 month low of $96.06 and a 12 month high of $133.55. The business's 50 day simple moving average is $127.30 and its 200 day simple moving average is $120.55.</p>
<div class="lb-trans"><p>诺华股票在周五开盘价为 126.49 美元。该公司的流动比率为 0.88，速动比率为 0.62，债务与股本比率为 0.50。该公司的市值为 2672 亿美元，市盈率为 17.25，PEG 比率为 1.93，贝塔值为 0.60。诺华 AG 的 12 个月低点为 96.06 美元，12 个月高点为 133.55 美元。该公司的 50 日简单移动平均线为 127.30 美元，200 日简单移动平均线为 120.55 美元。</p>
</div><ul>
<li>3 Momentum Stocks That Could Soar Post-Market Volatility</li>
</ul>
<div class="lb-trans"><ul>
<li>三只可能在市场波动后飙升的动量股</li>
</ul>
</div><p>Novartis (NYSE:NVS - Get Free Report) last announced its quarterly earnings data on Tuesday, October 28th. The company reported $2.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.26 by ($0.01). The firm had revenue of $13.91 billion during the quarter, compared to the consensus estimate of $13.70 billion. Novartis had a net margin of 26.49% and a return on equity of 41.21%. The company's revenue was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.06 earnings per share. Sell-side analysts forecast that Novartis AG will post 8.45 EPS for the current year.</p>
<div class="lb-trans"><p>诺华 (NYSE:NVS - 获取免费报告) 最近在 10 月 28 日宣布了其季度财报。该公司报告本季度每股收益 (EPS) 为 2.25 美元，低于分析师的共识预期 2.26 美元，差额为 0.01 美元。该公司本季度的收入为 139.1 亿美元，而共识预期为 137 亿美元。诺华的净利润率为 26.49%，股本回报率为 41.21%。该公司的收入同比增长 8.5%。在去年同期，该公司每股收益为 2.06 美元。卖方分析师预测诺华 AG 本年度将发布 8.45 美元的每股收益。</p>
</div><h2>About Novartis</h2>
<div class="lb-trans"><h2>关于诺华</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免费报告)</p>
</div><p>Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.</p>
<div class="lb-trans"><p>诺华 AG 从事医疗产品的研究、开发、生产和营销，业务遍及瑞士及国际市场。该公司为患者和医生提供处方药。其专注于心血管、肾脏和代谢、免疫学、神经科学和肿瘤学等治疗领域，以及眼科和血液学。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Novartis</li>
<li>Investing In Automotive Stocks</li>
<li>Getting Defensive: 3 Dividend Payers Reporting Strong Q3 Earnings</li>
<li>How to Invest in the FAANG Stocks</li>
<li>Why Investors Shouldn’t Fear the Dip in Microsoft Stock</li>
<li>Trading Stocks: RSI and Why it's Useful</li>
<li>DigitalOcean’s Tide Has Turned: Get Ready to Ride the Wave</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过诺华</li>
<li>投资汽车股票</li>
<li>防御性投资：三只报告强劲第三季度收益的分红股票</li>
<li>如何投资 FAANG 股票</li>
<li>为什么投资者不应害怕微软股票的下跌</li>
<li>股票交易：相对强弱指数及其用途</li>
<li>DigitalOcean 的潮流已转变：准备迎接浪潮</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WUw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=NVS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Novartis Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在诺华吗？</h2>
</div><p>Before you consider Novartis, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑诺华之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novartis wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议现在购买，以便在更广泛的市场注意到之前……而诺华并不在名单上。</p>
</div><p>While Novartis currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然诺华制药目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Zevin Asset Management LLC 出售了 2,173 股诺华制药（Novartis AG）的股票，代码为$NVS